Shuoshi Bio's former actual controllers Fang Yongsheng, Liang Xilin, and Wang Guoqiang signed an agreement on July 29 to prematurely terminate their concerted action relationship that had lasted over a decade, making Fang Yongsheng the company's sole actual controller. Although Fang Yongsheng does not hold shares directly, as the executive partner of the controlling shareholder Runkang Bio and several partnerships, he collectively controls the voting rights of 40.02 million company shares, representing 32.24% of the total share capital. Liang Xilin, as the main investor holding a 71.88% stake in Runkang Bio, has filed a lawsuit seeking the dissolution of Runkang Bio on the grounds that the partnership's purpose cannot be achieved; Fang Yongsheng holds only a 7.99% stake in Runkang Bio but controls the holding platform as executive partner. The Shanghai Stock Exchange has issued a regulatory work letter to Shuoshi Bio regarding the change in control, while the company's first-quarter 2026 non-recurring net loss was 4.01 million yuan, with operations remaining under pressure.
Jiangsu Bioperfectus Technologies Co LtdControlling shareholder sued for dissolution and concerted action terminated, with regulatory scrutiny from Shanghai Stock Exchange.
Runkang Bio is being sued for dissolution by a major investor, and its control structure is disrupted.